PAUL SAGAN - 13 Oct 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Director
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 13 Oct 2021
Net transactions value: -$708,525
Form type: 4
Filing time: 15 Oct 2021, 16:03:33 UTC
Previous filing: 13 Aug 2021
Next filing: 02 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Sale	$708,525	-2,250	-13%	$314.90	14,951	13 Oct 2021	By: Erwin Park LLC	F1, F2
holding	MRNA	Common Stock						76,452	13 Oct 2021	By: The Chatham Trust	F2
holding	MRNA	Common Stock						370,407	13 Oct 2021	By: The Paul Sagan Revocable Trust	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2021.
F2	Erwin Park LLC is an estate planning vehicle for the Reporting Person's family. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2021.

Erwin Park LLC is an estate planning vehicle for the Reporting Person's family. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.